Zentalis stock rises on cancer trial data (ZNTL:NASDAQ)

Wedbush upgraded Zentalis Pharmaceuticals to Outperform from Neutral, raising its price target to $6 from $5, a 20% increase. The target implies a 244.8% upside from the Nov 9 close of $1.74.

Zentalis Pharmaceuticals (ZNTL) stock rose 5.2% in pre-market trading after beating Q3 2026 earnings estimates with a loss of $0.34 per share, better than the $0.58 estimate. The company reported $228.89 million in cash and expects to complete a clinical trial by November 2026, with a readout in early 2027. Analysts maintain a 'Buy' rating with a $7.33 price target.

Zentalis Pharmaceuticals, Inc. (ZNTL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Zentalis Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Updates • DENALI Part 1b survival data strengthen azenosertib's position as the potential first-in-class oral, non-chemotherapy, non-ADC therapy in pivotal development for Cyclin E1-po

Zentalis Pharmaceuticals (ZNTL) reported interim results from its DENALI Part 1b study of azenosertib for ovarian cancer at the ESMO Congress. The trial showed median overall survival of 15.9 months in Cyclin E1-positive patients and 7.5 months in negative patients. The study enrolled 102 heavily pretreated patients, with a 33.3% objective response rate in evaluable Cyclin E1-positive patients. Common adverse events included nausea and fatigue.

Zentalis Pharmaceuticals reported interim data from DENALI Part 1b, showing median overall survival of 15.9 months in Cyclin E1-positive platinum-resistant ovarian cancer (PROC) patients, compared to 7.5 months in Cyclin E1-negative patients. The safety profile was consistent with prior reports, and the study supports azenosertib as a potential treatment. DENALI Part 2 and ASPENOVA Phase 3 trials are ongoing.

Zentalis Pharmaceuticals (ZNTL) presented interim data from the DENALI Part 1b study, showing median overall survival of 15.9 months for Cyclin E1-positive patients treated with azenosertib, compared to 7.5 months for Cyclin E1-negative patients. The study involved 102 heavily pretreated ovarian cancer patients. Zentalis is advancing azenosertib in ongoing Phase 3 trials for platinum-resistant ovarian cancer.